Recent Updates
Recently added Catalysts

Hypertrophic Cardiomyopathy: 4 biotech companies with clinical-stage programmes

Cardiovascular & MetabolicConcentrated betData as of 2026-09-04

Competitors4in the clinic
Median market cap$2.8Buniverse median $1.20B
Allocated capital$5.2B$14.9B competing
Phase 3 or filed21 mid, 1 early
Pure plays0this indication only
Capital rank36/299crowding rank 44

Hypertrophic Cardiomyopathy is a concentrated bet: only 4 US-listed developers are in the clinic, and the median one is worth $2.8B against a $1.20B universe median.

Scarcity is doing the work in that number. A thin field means an approval is shared with fewer rivals, and the market pays a premium for that position.

CYTK carries 62% of the $14.9B competing here, more than the other 3 companies combined.

$5.2B of allocated capital sits in Hypertrophic Cardiomyopathy, ranking it 36th of 299 indications by the money committed to it.

Companies developing drugs for Hypertrophic Cardiomyopathy 4

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
CYTKCytokineticsAficamtenPhase 32$9.2BNo4 14 Nov 2026
LXRXLexicon PharmaceuticalsSotagliflozinPhase 31$1.0BNo2 31 Dec 2026
EWTXEdgewise TherapeuticsEDG-7500Phase 21$4.6BNo2 31 Dec 2026
TNYATenaya TherapeuticsTN-201Phase 11$156MNo2 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. CYTK holds 62% of the $14.9B competing in this indication.

Why Hypertrophic Cardiomyopathy is a concentrated bet

Few competitors, each one large. The market pays a scarcity premium to compete here.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Hypertrophic Cardiomyopathy has 4 competitors and a median of $2.8B.

Cardiovascular & Metabolic

Cardiovascular & Metabolic holds $89.7B of the map's capital, 13.4% of the total, spread across 29 indications and 44 companies. 9 of those indications have more than one company competing.

See every Cardiovascular & Metabolic indication on the map

Related indications in Cardiovascular & Metabolic

Vasomotor Symptoms1 company · $3.5B · median $3.5BUncontestedPulmonary Arterial Hypertension3 companies · $7.1B · median $585MOrphan cornerDiabetes9 companies · $3.2B · median $401MKnife fightHypertriglyceridemia2 companies · $2.8B · median $10.9BConcentrated betChronic Heart Failure With Reduced Ejection Fraction1 company · $2.3B · median $9.2BUncontestedHeart Failure with Decompensation1 company · $2.3B · median $9.2BUncontestedCholestatic Liver Disease1 company · $2.2B · median $6.5BUncontestedATTR Amyloidosis2 companies · $2.0B · median $5.7BConcentrated bet

Hypertrophic Cardiomyopathy pipeline questions

Which biotech companies are developing drugs for Hypertrophic Cardiomyopathy?

Cytokinetics (CYTK, Aficamten, Phase 3); Lexicon Pharmaceuticals (LXRX, Sotagliflozin, Phase 3); Edgewise Therapeutics (EWTX, EDG-7500, Phase 2); Tenaya Therapeutics (TNYA, TN-201, Phase 1). Those are the 4 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Hypertrophic Cardiomyopathy.

How advanced is the Hypertrophic Cardiomyopathy pipeline?

Of the 4 clinical-stage programmes in Hypertrophic Cardiomyopathy, 2 are in Phase 3 or filed, 1 is in mid-stage development and 1 is in early-stage development.

Which company leads the Hypertrophic Cardiomyopathy field?

CYTK is the largest developer in Hypertrophic Cardiomyopathy, holding 62% of the $14.9B of market capitalisation competing in the indication. The median competitor is worth $2.8B.

When is the next Hypertrophic Cardiomyopathy catalyst?

The next dated catalyst in Hypertrophic Cardiomyopathy is CYTK on 14 Nov 2026. 4 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map